Now That's A Healthy BabyBy
Among this year's crop of initial public offerings, PharmaChem has already proven itself. Two weeks after the company went public on Aug. 12, bad news hit. The U. S. Postal Service, one of PharmaChem's biggest customers, announced that PharmaChem had lost in the bidding that might have renewed the company's contract to provide drug testing. But the stock refused to wilt.
PharmaChem, which went public at 8 1/2, had risen to 10 1/2 by Aug. 28. On Aug. 29, when the Post Office decision hit the newswires, the stock eased just to 10--and it's already back up to 10 1/2. Several big investors think it will continue to climb, possibly doubling in a year based on rosy earnings targets.
Even without the Post Office's business, says Andy Lanyi, who heads Ladenburg Thalmann's Lanyi Div., earnings will pop to 27~ this year and to 50~ in 1992, vs. last year's 13~.
PharmaChem's corporate customers include American Telephone & Telegraph, Pfizer, and Pennzoil. Among its government clients, the Army and the Probation Div. of the U. S. Courts are mainstays. Several large drug-treatment programs are also regulars.
PharmaChem is certified by the National Institute on Drug Abuse, the College of American Pathologists, and the Defense Dept. So it should hold its own against similarly certified giants such as SmithKline Beecham, notes Lanyi. And, he adds, the "feedback from customers is very positive."
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Comedian Byron Allen Buys the Weather Channel for $300 Million
- Stocks Tumble in Biggest Weekly Decline Since 2016: Markets Wrap
- Musk Takes Down the Tesla and SpaceX Facebook Pages
- Stocks Drop Most in Six Weeks on Trade War Tension: Markets Wrap
- World's Biggest Cryptocurrency Exchange Is Heading to Malta